{"id":9061,"date":"2026-05-20T23:00:00","date_gmt":"2026-05-20T21:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=453af1106c0afa72a0742ffef907eae8"},"modified":"2026-05-20T23:00:00","modified_gmt":"2026-05-20T21:00:00","slug":"vyriad-launches-g-link-a-modular-platform-advancing-t-cell-targeted-lentiviral-vector-delivery-for-in-vivo-and-ex-vivo-applications","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=9061","title":{"rendered":"Vyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo Applications"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>G-Link enables targeted in vivo delivery and streamlines ex vivo workflows without lentiviral vector reengineering<\/i><\/li>\n<li>\n<i>G-Link supports multiple delivery modalities while fitting directly into established vector development and manufacturing workflows<\/i><\/li>\n<\/ul><p>ROCHESTER, Minn.--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/hashtag\/ASGCT?src=hash\" >#ASGCT<\/a>--Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced the introduction of G-Link\u2122, a first-in-class modular adaptor protein technology designed to enable and enhance T-cell-targeting delivery across <i>in vivo<\/i> and <i>ex vivo <\/i>CAR T workflows. Data presented at the 2026 American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting demonstrate how G-Link integrates with lentiviral systems to improve precision, efficiency and scalability without adding operational complexity.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260520542438\/en\/2677531\/5\/Vyriad_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260520542438\/en\/2677531\/22\/Vyriad_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260520542438\/en\/2677531\/5\/Vyriad_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260520542438\/en\/2677531\/21\/Vyriad_Logo.jpg\" \/><\/a><p>\nG-Link \u2013 developed in collaboration with Menachem Rubinstein of the Weizmann Institute \u2013 is a \u201cplug-and-play\u201d protein adaptor that builds on the established performance of vesicular stomatitis virus G glycoprotein (VSV-G)\u2013pseudotyped lentiviral vectors (LVVs) by masking native low-density lipoprotein receptor (LDLR) tropism and retargeting delivery to CD3+ T cells without requiring complex vector redesign. Its trimeric architecture enables simultaneous engagement of the three protomers of VSV-G, enabling high-avidity attachment to the VSV-G protein and selective engagement of T cells and other cell types. Once internalized, the G-Link cap is released in the endosome, allowing normal membrane fusion and preserving vector function.<\/p><p>\n\u201cThis year\u2019s ASGCT reinforced what much of the industry already recognizes \u2014 delivery remains one of the most significant barriers for <i>in vivo<\/i> CAR T, and there is growing demand for practical solutions that can accelerate innovation, but with simplicity,\u201d said Dr. Luke Russell, executive vice president of Vyriad. \u201cMany current strategies require complex redesigns or manufacturing processes that can create friction at the exact moment the field needs scalability. G-Link was created to remove those barriers and help partners move quickly in <i>in vivo<\/i> CAR T - and, at the same time, simplify <i>ex vivo<\/i> workflows.\u201d<\/p><p>\n<b>G-Link for In Vivo CAR T: Targeted Delivery Platform With No Reengineering<\/b><\/p><p>\nAt ASGCT, preclinical data demonstrated that G-Link-capped lentiviral vectors carrying the same anti-BCMA CAR construct used in Vyriad\u2019s lead <i>in vivo <\/i><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvyriad.com%2Fnewsevents%2Fvyriad-unveils-lead-in-vivo-car-t-candidate-vv169-and-data-supporting-future-clinical-development-during-ash-2025%2F&amp;esheet=54539433&amp;newsitemid=20260520542438&amp;lan=en-US&amp;anchor=clinical+candidate&amp;index=1&amp;md5=cdd05e3a77dd79eedaf245da379544d7\" rel=\"nofollow\" shape=\"rect\">clinical candidate<\/a> VV169 \u2014 but pseudotyped with wild-type VSV-G \u2014 can generate functional CAR T cells <i>in vivo<\/i> with significant anti-tumor activity in an advanced OPM-2 human disseminated multiple myeloma xenograft model. The LVV leveraged a modified, T-cell-selective promoter within a reversed expression cassette to drive CAR expression in T cells and prevent incorporation into the viral envelope during packaging, reducing the risk of off-target transduction of malignant cells. Key findings from the study include:<\/p><ul class=\"bwlistdisc\">\n<li>\nComplete tumor clearance between days 14 and 28 post-treatment, including at the lowest tested dose<\/li>\n<li>\nCAR T cells were detectable by day 14 and declined following tumor elimination. Animals remained tumor-free upon rechallenge<\/li>\n<li>\nTreatment was well tolerated, with minimal cytokine elevation, stable body weight, and no observed toxicities<\/li>\n<li>\nIn a separate study, the G-Link maintained performance and tropism under clinical translation-relevant conditions, including freeze-thaw stress, downstream purification processes, and unfavorable settings such as room temperature, and highly diluted or detergent-heavy environments<\/li>\n<\/ul><p>\n<b>Versatility of G-Link Beyond LVV-Based In Vivo Indications<\/b><\/p><p>\nIn <i>ex vivo<\/i> settings, G-Link functions as a booster that enhances activation and transduction of T cells. When added alongside wild-type LVVs, G-Link enables efficient delivery without the need for T-cell sorting or activation steps. G-Link-capped LVVs were compared against engineered, CD3-targeted vectors for delivery of a CAR construct targeting human PSMA \u2013 an antigen highly expressed in prostate tumors \u2013 which found:<\/p><ul class=\"bwlistdisc\">\n<li>\nBoth platforms generated high-titer, CD3-targeted vectors that selectively transduced CD3+ cell populations within peripheral blood mononuclear cells and CD3+ Jurkat T cells, with no transduction observed in CD3-negative cell lines.<\/li>\n<li>\nTransduced T cells expressed the \u03b1PSMA-CAR and demonstrated functional activation, indicated by upregulated CD25 expression.<\/li>\n<\/ul><p>\nAdding to G-Link\u2019s versatility, additional data presented demonstrates the platform\u2019s ability to extend beyond lentiviral vectors and retarget Cas9-carrying engineered virus-like particles (eVLPs). In a \u03b22-microglobulin knockout study, G-Link blinded LDLR-mediated entry of the eVLP systems while driving efficient, CD3-specific edits.<\/p><p>\n\u201cThe real opportunity with G-Link is the versatility it introduces at the development level,\u201d said Dr. Kah-Whye Peng, chief technology officer of Vyriad. \u201cIt allows Vyriad and our partners to explore new targets and applications without being constrained by vector design, fundamentally accelerating how quickly and broadly we can move programs forward.\u201d<\/p><p>\nFor research applications, G-Link is available for purchase via <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fimanislife.com%2Fcollections%2Fg-link%2F&amp;esheet=54539433&amp;newsitemid=20260520542438&amp;lan=en-US&amp;anchor=Imanis+Life+Sciences&amp;index=2&amp;md5=a8fdd1dc87cdf3d23ede1aae3ed80e11\" rel=\"nofollow\" shape=\"rect\">Imanis Life Sciences<\/a>.<\/p><p>\nVyriad\u2019s VV169 <i>in vivo<\/i> CAR T program is expected to enter clinical development later this year, with the G-Link platform continuing to advance toward future clinical translation afterwards.<\/p><p>\n<b>About Vyriad<\/b><\/p><p>\nVyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company uses engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells. Vyriad\u2019s programs include oncolytic virotherapy, in vivo gene therapy, and gene editing applications, with ongoing Phase 1\u20132 trials in multiple cancer indications. Vyriad is a privately held company based in Rochester, Minnesota.<\/p><p>\nFor more information, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vyriad.com&amp;esheet=54539433&amp;newsitemid=20260520542438&amp;lan=en-US&amp;anchor=www.vyriad.com&amp;index=3&amp;md5=79346eef8aca24b2f83d8a9ecba96c6b\" rel=\"nofollow\" shape=\"rect\">www.vyriad.com<\/a><\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contact<\/b><br\/>Jakub Cikowski\n<br\/>HDMZ\n<br\/><a  href=\"mailto:vyriad.pr@hdmz.com\" rel=\"nofollow\" shape=\"rect\">vyriad.pr@hdmz.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>G-Link enables targeted in vivo delivery and streamlines ex vivo workflows without lentiviral vector reengineering<\/p>\n<p>G-Link supports multiple delivery modalities while fitting directly into established vector development and manufacturing workflows<br \/>\nRO&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9061","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9061"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9061\/revisions"}],"predecessor-version":[{"id":9062,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9061\/revisions\/9062"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}